Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Altimmune, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (THE "COMPANY," "OUR" OR "ALT5") (NASDAQ: ALTS) (FRA:5AR1), THE $WLFI DIGITAL ASSET TREASURY COMPANY, TODAY ISSUED A LETTER TO ITS STOCKHOLDERS: DEAR STOCKHOLDERS, YOU SHOULD HAVE RECEIVED BY MAIL A COPY OF THE PROXY MATERIALS FOR THE OCTOBER 10, 2025, SPECIAL MEETING OF THE STOCKHOLDERS OF ALT5 SIGMA CORPORATION. THE PROXY MATERIALS CONTAIN INSTRUCTIONS ON HOW TO VOTE YOUR SHARES, INCLUDING THE CONTROL NUMBER ASSOCIATED WITH YOUR PROXY CARD. I.

ALT5 SIGMA ISSUES LETTER TO STOCKHOLDERS

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (THE "COMPANY," "OUR" OR "ALT5") (NASDAQ: ALTS) (FRA:5AR1), THE $WLFI DIGITAL ASSET TREASURY COMPANY, TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN A.G.P. (ALLIANCE GLOBAL PARTNERS) DIGITAL ASSETS & TECHNOLOGY (DAT) SHOWCASE ON OCTOBER 8, 2025, AT 9:00 A.M. ET. THE PRESENTATION WILL FEATURE JONATHAN HUGH, CHIEF FINANCIAL OFFICER OF ALT5 SIGMA, ALONGSIDE ZAK FOLKMAN, CO-FOUNDER OF WORLD LIBERTY FINANCIAL, AND MATT MORGAN, ADVISOR TO WORLD LIBE.

ALT5 SIGMA AND WORLD LIBERTY FINANCIAL TO PRESENT AT A.G.P.'S DIGITAL ASSETS & TECHNOLOGY SHOWCASE

NEW YORK--(BUSINESS WIRE)-- #CLASSACTION--FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ALTIMMUNE, INC. (ALTIMMUNE OR THE COMPANY) (NASDAQ: ALT) AND REMINDS INVESTORS OF THE OCTOBER 6, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. FARUQI & FARUQI IS A LEADING NATIONAL SECURITIES LAW FIRM WITH OFFICES IN NEW YORK, PENNSYLVANIA, CALIFORNIA AND GEORGIA. THE FIRM H.

FINAL DEADLINE ALERT: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE

ALTIMMUNE ALLEGEDLY MISLED INVESTORS ON PEMVIDUTIDE'S MASH TRIAL, WHICH FAILED ITS KEY FIBROSIS ENDPOINT, CAUSING SHARES TO PLUNGE 53% ON JUNE 26, 2025.

ALTIMMUNE FINAL DEADLINE REMINDER: BRAGAR EAGEL & SQUIRE, P.C. URGES INVESTORS TO CONTACT THE FIRM REGARDING THE OCTOBER 6TH DEADLINE

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (THE "COMPANY," "OUR" OR "ALT5") (NASDAQ: ALTS) (FRA:5AR1), THE $WLFI DIGITAL ASSET TREASURY COMPANY, TODAY HIGHLIGHTED RECENT ADVANCEMENTS IN THE $WLFI ECOSYSTEM THAT THE COMPANY BELIEVES WILL SUBSTANTIALLY STRENGTHEN THE $WLFI TOKEN, THE ASSET ON WHICH THE COMPANY'S DIGITAL ASSET TREASURY STRATEGY IS BASED  THE LAUNCH OF $WLFI ON ROBINHOOD, AND WORLD LIBERTY FINANCIAL'S PLANNED INTRODUCTION OF A WLFI-BRANDED DEBIT CARD, WHICH WOULD ALLOW USD.

ALT5 SIGMA TREASURY STRATEGY STRENGTHENED BY ACCELERATING $WLFI ADOPTION DRIVEN BY ROBINHOOD LAUNCH AND POTENTIAL APPLE PAY INTEGRATION WITH USD1

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN ALTIMMUNE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

ALT INVESTOR NOTICE: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN ALTIMMUNE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN ALTIMMUNE BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , OCT. 3, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) AND REMINDS INVESTORS OF THE OCTOBER 6, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

SHAREHOLDER REMINDER: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE

NEW YORK , OCT. 1, 2025 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) OF A CLASS ACTION SECURITIES LAWSUIT. CLASS DEFINITION: THE LAWSUIT SEEKS TO RECOVER LOSSES ON BEHALF OF ALTIMMUNE INVESTORS WHO WERE ADVERSELY AFFECTED BY ALLEGED SECURITIES FRAUD BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025.

INVESTORS IN ALTIMMUNE, INC. SHOULD CONTACT LEVI & KORSINSKY BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS - ALT

LOS ANGELES--(BUSINESS WIRE)--ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  ALT.

ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS  ALT

INVESTOR DEADLINE APPROACHING: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE

SEASONED CLINICAL LEADER TO OVERSEE PHASE 3 DEVELOPMENT OF PEMVIDUTIDE IN MASH DR. ARBET-ENGELS HAS LED LATE-STAGE DEVELOPMENT, REGULATORY APPROVALS AND COMMERCIAL LAUNCHES FOR MULTIPLE SUCCESSFUL FRANCHISES GAITHERSBURG, MD., SEPT. 29, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF CHRISTOPHE ARBET-ENGELS, MD, PHD AS CHIEF MEDICAL OFFICER, EFFECTIVE OCTOBER 1, 2025.

ALTIMMUNE APPOINTS INDUSTRY VETERAN CHRISTOPHE ARBET-ENGELS, M.D., PHD AS CHIEF MEDICAL OFFICER TO DRIVE NEXT PHASE OF CLINICAL DEVELOPMENT OF PEMVIDUTIDE

NEW YORK , SEPT. 25, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OFALTIMMUNE, INC. (NASDAQ: ALT).

INVESTORS IN ALTIMMUNE, INC. SHOULD CONTACT THE GROSS LAW FIRM BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS - ALT

GAITHERSBURG, MD., SEPT. 23, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT MEMBERS OF THE COMPANY'S MANAGEMENT TEAM WILL PARTICIPATE AND BE AVAILABLE FOR 1X1 MEETINGS AT THE FOLLOWING INVESTOR CONFERENCES:

ALTIMMUNE TO PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $75,000 IN ALTIMMUNE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

SHAREHOLDER NOTICE: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE

GAITHERSBURG, MD., SEPT. 15, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF LINDA M.

ALTIMMUNE APPOINTS ACCOMPLISHED COMMERCIAL EXECUTIVE LINDA M. RICHARDSON AS CHIEF COMMERCIAL OFFICER

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $75,000 IN ALTIMMUNE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED LOSSES EXCEEDING $75,000 IN ALTIMMUNE BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , SEPT.

NEW YORK, SEPT. 11, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) OF A CLASS ACTION SECURITIES LAWSUIT.

SHAREHOLDERS OF ALTIMMUNE, INC. SHOULD CONTACT LEVI & KORSINSKY BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS  ALT

NEW YORK , SEPT. 11, 2025 /PRNEWSWIRE/ -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF ALTIMMUNE, INC. (NASDAQ: ALT).

ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS - INVESTORS SHOULD CONTACT THE GROSS LAW FIRM BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS - ALT

NEW YORK , SEPT. 9, 2025 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) OF A CLASS ACTION SECURITIES LAWSUIT.

ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS - INVESTORS SHOULD CONTACT LEVI & KORSINSKY FOR MORE INFORMATION - ALT

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN ALTIMMUNE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN ALTIMMUNE BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , SEPT.

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (THE COMPANY, OUR OR ALT5) (NASDAQ: ALTS) (FRA:5AR1), A FINTECH SPECIALIZING IN TURNKEY, CRYPTO-RELATED SOLUTIONS FOR INSTITUTIONS AND MERCHANTS, TODAY ANNOUNCED AN UPDATE TO ITS $WLFI HOLDINGS. AS OF THIS RELEASE, ALT5 HOLDS APPROXIMATELY 7.28 BILLION $WLFI TOKENS. IN ADDITION, THE COMPANY IS HIGHLIGHTING THAT THE $WLFI TOKEN  THE FOUNDATIONAL DIGITAL ASSET UNDERPINNING ITS DIGITAL ASSET TREASURY STRATEGY  IS CURRENTLY AVAILABLE FOR TR.

ALT5 SIGMA CORPORATION ANNOUNCES $WLFI HOLDINGS RISE TO APPROXIMATELY 7.28 BILLION TOKENS

NEW YORK, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) OF A CLASS ACTION SECURITIES LAWSUIT.

INVESTORS IN ALTIMMUNE, INC. SHOULD CONTACT LEVI & KORSINSKY BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS  ALT

NEW YORK , SEPT. 2, 2025 /PRNEWSWIRE/ -- LEVI &KORSINSKY, LLP NOTIFIES INVESTORS IN ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) OF A CLASS ACTION SECURITIES LAWSUIT.

SHAREHOLDERS OF ALTIMMUNE, INC. SHOULD CONTACT LEVI & KORSINSKY BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS - ALT

NEW YORK, AUG. 27, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF ALTIMMUNE, INC. (NASDAQ: ALT).

ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT THE GROSS LAW FIRM BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS  ALT

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN ALTIMMUNE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED PURCHASED OR ACQUIRED SECURITIES IN ALTIMMUNE BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , AUG. 27, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) AND REMINDS INVESTORS OF THE OCTOBER 6, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

NEW YORK , AUG. 26, 2025 /PRNEWSWIRE/ -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) OF A CLASS ACTION SECURITIES LAWSUIT. CLASS DEFINITION: THE LAWSUIT SEEKS TO RECOVER LOSSES ON BEHALF OF ALTIMMUNE INVESTORS WHO WERE ADVERSELY AFFECTED BY ALLEGED SECURITIES FRAUD BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025.

ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS - INVESTORS SHOULD CONTACT LEVI & KORSINSKY BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS - ALT

GAITHERSBURG, MD., AUG. 26, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE AND BE AVAILABLE FOR ONE-ON-ONE MEETINGS AT THE FOLLOWING INVESTOR CONFERENCES:

ALTIMMUNE TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

NEW YORK, AUG. 21, 2025 (GLOBE NEWSWIRE) -- THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE TO SHAREHOLDERS OF ALTIMMUNE, INC. (NASDAQ: ALT).

ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE GROSS LAW FIRM BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS  ALT

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $75,000 IN ALTIMMUNE TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED LOSSES EXCEEDING $75,000 IN ALTIMMUNE BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , AUG. 21, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) AND REMINDS INVESTORS OF THE OCTOBER 6, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

SHAREHOLDER ACTION REMINDER: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE

NEW YORK, AUG. 19, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) OF A CLASS ACTION SECURITIES LAWSUIT.

ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT LEVI & KORSINSKY BEFORE OCTOBER 6, 2025 TO DISCUSS YOUR RIGHTS  ALT

PEMVIDUTIDE IS THE ONLY DRUG CURRENTLY GRANTED FAST TRACK DESIGNATION IN AUD RECLAIM, A PHASE 2 TRIAL OF PEMVIDUTIDE IN AUD, IS CURRENTLY ENROLLING GAITHERSBURG, MD., AUG. 19, 2025 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING PEPTIDE-BASED THERAPEUTICS FOR LIVER AND CARDIOMETABOLIC DISEASES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED FAST TRACK DESIGNATION TO PEMVIDUTIDE FOR THE TREATMENT OF ALCOHOL USE DISORDER (AUD).

ALTIMMUNE ANNOUNCES FDA FAST TRACK DESIGNATION FOR PEMVIDUTIDE IN ALCOHOL USE DISORDER (AUD)

NEW YORK , AUG. 18, 2025 /PRNEWSWIRE/ -- ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES THAT A SHAREHOLDER FILED A CLASS ACTION ON BEHALF OF PURCHASERS OF SECURITIES ALTIMMUNE, INC. (NASDAQ: ALT) BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025 (THE "CLASS PERIOD"). IF YOU WISH TO SERVE AS LEAD PLAINTIFF, YOU MUST MOVE THE COURTNO LATER THAN OCTOBER 6, 2025.

ROSEN LAW FIRM URGES ALTIMMUNE, INC. (NASDAQ: ALT) STOCKHOLDERS TO CONTACT THE FIRM FOR INFORMATION ABOUT THEIR RIGHTS

NEW YORK, AUG. 17, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. (ALTIMMUNE OR THE COMPANY) (NASDAQ: ALT). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. - ALT

NEW YORK , AUG. 16, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC.("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

PHILADELPHIA , AUG. 15, 2025 /PRNEWSWIRE/ -- BERGER MONTAGUE PC IS INVESTIGATING POTENTIAL SECURITIES FRAUD CLAIMS ON BEHALF OF INVESTORS OFALTIMMUNE, INC. (NASDAQ: ALT) ("ALTIMMUNE" OR THE "COMPANY") FOLLOWING THE FILING OF A SECURITIES CLASS ACTION LAWSUIT FILED ON BEHALF OF INVESTORS WHO PURCHASED OR OTHERWISE ACQUIRED ALTIMMUNE SECURITIES BETWEEN AUGUST 10, 2023 THROUGH JUNE 25, 2025 (THE "CLASS PERIOD"). INVESTOR DEADLINE: INVESTORS WHO PURCHASED OR ACQUIRED ALTIMMUNE SECURITIES DURING THE CLASS PERIOD MAY, NO LATER THAN OCTOBER 6, 2025 , SEEK TO BE APPOINTED AS A LEAD PLAINTIFF REPRESENTATIVE OF THE CLASS.

BERGER MONTAGUE PC INVESTIGATES SECURITIES CLAIMS AGAINST ALTIMMUNE, INC. (NASDAQ: ALT)

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (NASDAQ: ALTS)(FRA: 5AR1) (THE COMPANY OR ALT5), A FINTECH AND DIGITAL ASSET TREASURY (DAT) COMPANY SPECIALIZING IN TURNKEY, CRYPTO-RELATED SOLUTIONS FOR INSTITUTIONS AND MERCHANTS, TODAY ANNOUNCED THE APPOINTMENT OF INDUSTRY VETERAN JONATHAN HUGH AS CFO OF THE COMPANY. FOLLOWING ALT5 SIGMA'S RECENTLY ANNOUNCED $1.5 BILLION FINANCING AND THE LAUNCH OF THE COMPANY'S $WLFI TREASURY STRATEGY, WE ARE PLEASED TO ANNOUNCE THE APPOINTMENT OF JONAT.

ALT5 SIGMA CORPORATION APPOINTS JONATHAN HUGH AS CFO

NEW YORK, AUG. 14, 2025 (GLOBE NEWSWIRE) -- LEVI & KORSINSKY, LLP NOTIFIES INVESTORS IN ALTIMMUNE, INC. ("ALTIMMUNE" OR THE "COMPANY") (NASDAQ: ALT) OF A CLASS ACTION SECURITIES LAWSUIT.

ALTIMMUNE, INC. SUED FOR SECURITIES LAW VIOLATIONS  INVESTORS SHOULD CONTACT LEVI & KORSINSKY FOR MORE INFORMATION  ALT

NEW YORK , AUG. 13, 2025 /PRNEWSWIRE/ --ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, ANNOUNCES THAT A SHAREHOLDER FILED A CLASS ACTION ON BEHALF OF PURCHASERS OF SECURITIES ALTIMMUNE, INC. (NASDAQ: ALT) BETWEEN AUGUST 10, 2023 AND JUNE 25, 2025 (THE "CLASS PERIOD"). IF YOU WISH TO SERVE AS LEAD PLAINTIFF, YOU MUST MOVE THE COURTNO LATER THAN OCTOBER 6, 2025.

NEW YORK, AUG. 13, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ALTIMMUNE, INC. (ALTIMMUNE OR THE COMPANY) (NASDAQ: ALT).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMSON BEHALF OF INVESTORS OF ALTIMMUNE, INC. - ALT

LAS VEGAS--(BUSINESS WIRE)--ALT5 SIGMA CORPORATION (THE COMPANY, OUR OR ALT5) (NASDAQ: ALTS) (FRA:5AR1), A FINTECH SPECIALIZING IN TURNKEY, CRYPTO-RELATED SOLUTIONS FOR INSTITUTIONS AND MERCHANTS, WELCOMES ZACH WITKOFF, CO-FOUNDER AND CEO OF WORLD LIBERTY FINANCIAL, INC. (WLFI), AS CHAIRMAN OF ITS BOARD OF DIRECTORS (THE BOARD), EFFECTIVE UPON THE CLOSING OF ITS PREVIOUSLY ANNOUNCED $1.5 BILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT. THE PREVIOUSLY ANNOUNCED FINA.

Altimmune, Inc.

ALT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Altimmune, Inc.

ALT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ALT